In 2013, the first 225Ac-labeled PSMA small-molecule ligand PSMA-617 for targeted prostate cancer therapy was developed and investigated at Joint Research Center (JRC) Karlsruhe. This evidence concerns the gene FOLH1 and prostate carcinoma.